Doctors on Saturday praised "unprecedentedly strong responses” to an injection that eradicated entire tumors in otherwise treatment-resistant cancer cases during a trial.
It shrank the tumors for 42% of patients in the study by the Institute of Cancer Research (ICR), London.
Scientists gave amivantamab to people with recurrent and/or metastatic head and neck cancer that had stopped responding to standard treatments.
Amivantamab is a small injection, unlike many cancer medications that require intravenous drips.
One participant with tongue cancer said the treatment reduced his pain and swelling and he is no longer experiencing the "life-impacting” side effects he had during chemotherapy.
